## CAH: Cardinal Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.1% below STRENGTH zone (3.0-6.0%); PEG 1.95 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($199.04)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Cardinal Health (CAH) Repositions for Growth with Specialty and Services**
- Source: Insider Monkey | 20260103T001013 | Bullish | Relevance: 100%
- Cardinal Health (NYSE:CAH) has shown strong performance by shifting its focus to higher-margin specialty pharmaceuticals and managed services, leading to increased earnings growth and a favorable dividend payout ratio. The company recently raised its fiscal 2026 outlook, anticipating adjusted earnings per share between $9.65 and $9.85, reflecting robust first-quarter results and the upcoming acquisition of Solaris Health. While CAH is considered a strong investment, the article suggests that certain AI stocks may offer even greater upside potential.

**2. Cardinal Health (CAH) repositions for growth with specialty and services**
- Source: MSN | 20260104T230804 | Bullish | Relevance: 100%
- Cardinal Health is strategically repositioning itself by focusing on specialty pharmaceuticals and services. This move aims to leverage the growing market for complex therapies and enhance its service offerings, departing from its traditional distribution model to drive future growth and profitability. The company is investing in advanced logistics and data analytics to support this shift.

**3. Palliative Care Market See Incredible Growth 2025-2032 | Cardinal Health, Humana Inc., McKesson Corporation, CVS Health Corporation**
- Source: openPR.com | 20260105T090757 | Bullish | Relevance: 100%
- The global Palliative Care Market is projected to grow from USD 9.4 billion in 2025 to USD 15.7 billion by 2032, exhibiting a CAGR of 7.8%. This growth is driven by rapid innovation and shifting regional dynamics, with key players like Cardinal Health, Humana Inc., and McKesson Corporation leading the market. The report segments the market by service type, disease type, and end-user, providing strategic insights for decision-makers.

**4. Cardinal Health (CAH) repositions for growth with specialty and services**
- Source: MSN | 20260105T120750 | Bullish | Relevance: 100%
- This article discusses Cardinal Health's strategic shift to focus on specialty pharmaceutical distribution and healthcare services. This repositioning is aimed at driving future growth for the company by leveraging higher-growth market segments.

**5. McKesson Builds Earnings Momentum on Specialty and Automation**
- Source: TradingView — Track All Markets | 20260105T190833 | Neutral | Relevance: 70%
- McKesson delivered a strong fiscal second quarter with consolidated revenues of $103 billion, up 10% year-over-year, and adjusted earnings per diluted share rising 39% to $9.86, leading management to raise full-year guidance. The company’s growth is driven by its North American Pharmaceutical distribution, accelerating specialty volumes, and rising contributions from prescription technology services, particularly within oncology and multispecialty segments. McKesson's long-term strategy focuses on scaling differentiated specialty platforms, leveraging technology and automation for efficiency, and expanding its presence in the biopharma and provider ecosystem.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $243 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 11 ($0.00M) |
| Sells | 5 ($0.41M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Blackrock Inc.: 13.2% (+3.0%)
- Vanguard Group Inc: 13.0% (+0.8%)
- State Street Corpora: 5.2% (-3.0%)
- Geode Capital Manage: 2.7% (+1.5%)
- Wellington Managemen: 2.4% (+153.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.95 elevated, pricing in significant growth expectations. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $48.8B |
| Beta | 0.65 |
| 52W Range | $119.00 - $214.93 |
| Short Interest | 2.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.95 |
| Forward P/E | 18.5 |
| Current P/E | 20.9 |
| YoY Growth | 12.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.1% to -0.1% (-1.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.1pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 59. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.07% (CS: 39) | Neutral |
| RSI_14 | 59.2 | Neutral |
| MACD Histogram | -0.17 | Bearish |
| vs SMA20 | 1.015x | Above |
| vs SMA50 | 1.032x | Above |
| vs SMA200 | 1.260x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $205.44
- **Stop Loss:** $199.04 (3.1% risk)
- **Target:** $211.84 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 134
- **Position Value:** $27,528.96
- **Portfolio %:** 27.53%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-01-29 (Est: $2.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.17 | $2.55 | +17.6% |
| 2025Q2 | $2.03 | $2.08 | +2.4% |
| 2025Q1 | $2.15 | $2.35 | +9.4% |
| 2024Q4 | $1.76 | $1.93 | +9.4% |

---
*RULE-based L3 | 2026-01-07 09:35 | MRS_10*